Anhydro Erythromycin A is primarily used as an intermediate in the synthesis of semi-synthetic macrolide antibiotics. It plays a key role in the production of derivatives like azithromycin and clarithromycin, which exhibit improved acid stability, better bioavailability, and broader antimicrobial activity compared to erythromycin. Due to its structural properties, it is valuable in pharmaceutical research for modifying the erythromycin core to overcome bacterial resistance and enhance pharmacokinetics. It is not used directly as a therapeutic agent but is essential in optimizing next-generation macrolide antibiotics for treating respiratory, skin, and soft tissue infections.